- Home
- CLLS vs GLO Comparison
CLLS vs GLO Comparison
Compare CLLS & GLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- GLO
- Stock Information
- Founded
- CLLS 1999
- GLO 2006
- Country
- CLLS France
- GLO United States
- Employees
- CLLS N/A
- GLO N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- GLO Finance/Investors Services
- Sector
- CLLS Health Care
- GLO Finance
- Exchange
- CLLS Nasdaq
- GLO Nasdaq
- Market Cap
- CLLS 240.2M
- GLO 220.1M
- IPO Year
- CLLS 2007
- GLO N/A
- Fundamental
- Price
- CLLS $1.57
- GLO $5.15
- Analyst Decision
- CLLS Buy
- GLO
- Analyst Count
- CLLS 3
- GLO 0
- Target Price
- CLLS $7.00
- GLO N/A
- AVG Volume (30 Days)
- CLLS 59.8K
- GLO 170.5K
- Earning Date
- CLLS 11-04-2024
- GLO 01-01-0001
- Dividend Yield
- CLLS N/A
- GLO 11.38%
- EPS Growth
- CLLS N/A
- GLO N/A
- EPS
- CLLS N/A
- GLO N/A
- Revenue
- CLLS $36,042,000.00
- GLO N/A
- Revenue This Year
- CLLS $271.02
- GLO N/A
- Revenue Next Year
- CLLS $33.48
- GLO N/A
- P/E Ratio
- CLLS N/A
- GLO N/A
- Revenue Growth
- CLLS 46.96
- GLO N/A
- 52 Week Low
- CLLS $1.53
- GLO $4.08
- 52 Week High
- CLLS $3.55
- GLO $5.18
- Technical
- Relative Strength Index (RSI)
- CLLS 27.91
- GLO 27.44
- Support Level
- CLLS $1.85
- GLO $5.00
- Resistance Level
- CLLS $2.09
- GLO $5.33
- Average True Range (ATR)
- CLLS 0.09
- GLO 0.06
- MACD
- CLLS -0.04
- GLO -0.03
- Stochastic Oscillator
- CLLS 0.00
- GLO 15.23
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
About GLO Clough Global Opportunities Fund
Clough Global Opportunities Fund is a closed-end management investment company based in the United States. Its investment objective is to provide a high level of total return. The fund invests in a mix of U.S. and non-U.S. equity and debt securities.